Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 441 to 450 of 1520 total matches.
Intracavernous Injections For Impotence
The Medical Letter on Drugs and Therapeutics • Dec 28, 1990 (Issue 834)
have not been detected in some large studies with alprostadil (W
The Medical Letter, Vol. 32 (Issue 834) December 28 ...
Self-injection of papaverine, a smooth muscle relaxant, and phentolamine (Regitine), an alpha-adrenergic blocker, directly into the corpus cavernosum has been effective for treatment of impotence in some patients, even after complete quadriplegia, radical surgery for bladder or prostate cancer, or castration (Medical Letter, 29:95, 1987). Recently, injections of prostaglandin E1, now called alprostadil (Prostin VR - Upjohn), have also been tried for this purpose. No drug is approved for this use by the US Food and Drug Administration.
Rapid Diagnostic Tests For Group A Streptococcal Pharyngitis
The Medical Letter on Drugs and Therapeutics • May 03, 1991 (Issue 843)
on next page)
The Medical Letter, Vol. 33 (Issue 843) May 3, 1991, pp. 40-41
Copyright The Medical ...
Antibiotic treatment of group A streptococcal pharyngitis can relieve symptoms, limit transmission of infection, and prevent suppurative and nonsuppurative sequelae. Clinical findings may be unreliable, however, in establishing the diagnosis, and conventional throat cultures take overnight or longer to produce results. Rapid office tests for streptococcal pharyngitis can make the diagnosis in about 10 minutes. Since the previous Medical Letter article on this subject (Medical Letter, 27:49, 1985), many new tests have been marketed, including some that use new technologies.
Bepridil for Angina Pectoris
The Medical Letter on Drugs and Therapeutics • May 31, 1991 (Issue 845)
(Cardizem), found that substituting
The Medical Letter, Vol. 33 (Issue 845) May 31, 1991, pp. 53-54 ...
Bepridil hydrochloride (Vascor - McNeil Pharmaceutical/Wallace Laboratories), a calcium-channel blocking agent chemically unrelated to verapamil (Calan, and others), nifedipine (Procardia, and others), or other drugs in this class, was recently approved by the US Food and Drug Administration for oral treatment of chronic stable angina pectoris. Because of its potential adverse effects, the labeling recommends reserving the drug for patients who fail to respond optimally to or are intolerant of other antianginal agents.
Ondansentron To Prevent Vomiting After Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • Jun 28, 1991 (Issue 847)
(Cytoxan, and others), doxorubicin (Adriamycin, and others) or
The Medical Letter, Vol. 33 (Issue 847 ...
Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An oral formulation is available in many other countries.
Sinemet CR For Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Oct 04, 1991 (Issue 854)
, Vol. 33 (Issue 854) October 4, 1991, pp. 92-93
Copyright The Medical Letter
UNAUTHORIZED ...
Controlled-release carbidopa/levodopa (Sinemet CR - Dupont Pharma) was recently approved by the US Food and Drug Administration for treatment of Parkinson's disease. The new formulation of this old combination (Sinemet) has the drugs suspended in a polymeric matrix that erodes slowly in the gastrointestinal tract.
Monoclonal For Gram-Negative Sepsis
The Medical Letter on Drugs and Therapeutics • Nov 01, 1991 (Issue 856)
Med, 324:429, 1991).
The Medical Letter, Vol. 33 (Issue 856) November 1, 1991, pp. 103-104
Copyright ...
HA-1A (Centoxin - Centocor), a monoclonal IgM antibody against endotoxin from gram-negative bacteria, may soon be approved for marketing by the US Food and Drug Administration. Commercially available in Europe, HA-1A has been used in the USA as an investigational drug. E5 (Xomen - Xoma), another monoclonal IgM antibody against endotoxin, is also available here for investigational use.
Lasers Treatment of Cutaneous Vascular Abnormalities
The Medical Letter on Drugs and Therapeutics • Nov 01, 1991 (Issue 856)
occur after treatment, but resolve within two weeks.
The Medical Letter, Vol. 33 (Issue 856) November 1 ...
In recent years, the availability of new types of lasers has improved the treatment of disfiguring cutaneous vascular abnormalities. Vascular lesions of the skin that can be treated with lasers include port-wine stains, telangiectases, and strawberry hemangiomas (RA Silverman, Pediatr Clin North Am, 38:811, Aug 1991).
Prevention And Treatment of Cholera
The Medical Letter on Drugs and Therapeutics • Nov 15, 1991 (Issue 857)
preparation can be made by adding 50 grams of precooked rice cereal to one liter of
The Medical Letter, Vol ...
Almost 300,000 cases of epidemic cholera have occurred in the Western Hemisphere in 1991, mostly in South and Central America (Morbid Mortal Weekly Rep, 40:562, Aug 16, 1991). The few US cases caused by the epidemic strain have been in returning travelers or associated with contaminated food they brought back illicitly, with no secondary spread to date.
Sertraline For Treatment Of Depression
The Medical Letter on Drugs and Therapeutics • May 15, 1992 (Issue 870)
, diarrhea, insomnia,
The Medical Letter, Vol. 34 (Issue 870) May 15, 1992, pp. 47-48
Copyright ...
Sertraline (Zoloft - Roerig), a serotonin reuptake inhibitor, was recently approved for marketing by the US Food and Drug Administration for treatment of depression. Another serotonin reuptake inhibitor, fluoxetine (Prozac), is prescribed more frequently in the USA than any other antidepressant (Medical Letter, 32:83, 1990).
Ticlopidine
The Medical Letter on Drugs and Therapeutics • Jul 10, 1992 (Issue 874)
found that, over six months, vascular death or myocardial infarction occurred
The Medical Letter, Vol ...
hydrochloride (Ticlid - Syntex), a platelet aggregation inhibitor that has been available in Europe for more than a decade, was recently approved by the U.S. Food and Drug Administration to decrease the risk of thrombotic stroke in men and women who have had premonitory signs of stroke or have had a completed thrombotic stroke. The manufacturer is promoting the drug for patients intolerant to aspirin or with conditions for which aspirin has not been approved (previous thrombotic stroke; transient ischemic attacks in women). The drug has also been used for prevention of myocardial ...